Table 11.
(A) Quality of life of non- metastatic gastric cancer, (patient’s received intervention and chemotherapy simultaneously). (B) Median difference before–after of quality of life
| Mean (before) |
Std. deviation |
Std. error |
P-value | Mean (after) |
Std. deviation |
Std. deviation |
P-value | |
|---|---|---|---|---|---|---|---|---|
| (A) Quality of life in patients with non-metastatic gastric cancer | ||||||||
| Global quality (BCc1 nanomedicine) |
38.29 | 10.045 | 3.797 | 0.200 | 37.57 | 11.267 | 4.259 | 0.200 |
| Global quality (Placebo) |
50.75 | 10.931 | 3.155 | 0.200 | 54.58 | 12.176 | 3.515 | 0.200 |
| Mean* | Std. deviation | Std. error mean | P-value | |
|---|---|---|---|---|
| (B) Median difference (before–after) of quality of life | ||||
| Quality of BCc1 (before–after) | 0.714 | 6.184 | 2.337 | 0.077 |
| Quality of Placebo (before–after) | − 3.833 | 5.441 | 1.571 | 0.033 |
* Higher score show better global quality of life